Ownership
Private
Employees
~50
Stage
Phase 3
Modalities
Small molecule

InCarda Therapeutics General Information

Phase 2 INSTANT trial showed rapid conversion from atrial fibrillation to normal sinus rhythm. Phase 3 RESTORE-1 trial results showed statistically significant cardioversion but was prematurely terminated.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Newark, California
United States

Drug Pipeline

flecainide
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to InCarda Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

InCarda Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view InCarda Therapeutics's complete valuation and funding history, request access »

InCarda Therapeutics Investors

Innoviva, Inc.
Investor Type: Venture Capital
Holding: Minority
Deerfield Management
Investor Type: Venture Capital
Holding: Minority
HealthCap
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »